In this study we will test the study hypothesis whether there is differential gene expression between patients with a history of premature MI and healthy controls when testing RNA obtained from highly purified platelets and monocytes.
ID
Source
Brief title
Condition
- Coronary artery disorders
- Arteriosclerosis, stenosis, vascular insufficiency and necrosis
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
The discovery of genetic markers in platelet- and monocyte- genes, key players
in atherosclerotic disease and atherothrombosis, may allow stratification of
CAD risk and the tailoring of preventative and therapeutic treatment.
Secondary outcome
not applicable
Background summary
The risk of cardiovascular disease is determined by the interplay between an
individual*s genetic background, lifestyle and environment. Twin studies have
demonstrated a substantial genetic component for cardiovascular disease with a
concordance of 20% and several risk genes have already been discovered.
However, genetic markers to predict the risk of atherothrombosis are currently
not available. The discovery of such markers will allow stratification of risk
and the tailoring of preventive and therapeutic treatment.
The Bloodomics project (www.bloodomics.org) focuses on the genetics and cell
biology of platelets and monocytes, since it is hypothesized that the magnitude
of response of these blood cells to vascular injury is critical in determining
whether thrombus formation will lead to arterial blood vessel occlusion and
thus MI ensues.
Study objective
In this study we will test the study hypothesis whether there is differential
gene expression between patients with a history of premature MI and healthy
controls when testing RNA obtained from highly purified platelets and
monocytes.
Study design
After obtaining written informed consent 150 ml of blood will be taken by
venepuncture. Platelets and monocytes will be purified by highly standardised
and validated techniques. RNA will be extracted from the platelets and
monocytes. The RNA will then be used for gene expression profiling using
several possible array platforms (e.g. Affymetrix, Illumina, *in-house*
generated spotted arrays) and for other quantitative and semi-quantitative
techniques (e.g. real-time RT-PCR by Taqman). RNA may also be used to generate
cDNA for sequencing.
Comparing results from cases and controls will identify genes that are
differentially expressed. Some or all of the genes that are identified as being
differentially expressed may be validated using quantitative real-time PCR.
Study burden and risks
The risk for the participants is minimal and only releted to venapuncture
Meibergdreef 9
1105 AZ Amsterdam
Nederland
Meibergdreef 9
1105 AZ Amsterdam
Nederland
Listed location countries
Age
Inclusion criteria
*Caucasoid
*Between 18 and 35 years of age for male patients and 18 and 45 years for female ones.
*History of confirmed MI according to WHO criteria
*Positive family history for premature CAD in a first degree relative.
*Informed Consent
Exclusion criteria
Current clinical CAD,
Current infection,
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL12984.018.06 |